Alex Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Alex Zhu has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Chao Qi
Department of Pathology, Northwestern University Feinberg School of Medicine
2 shared publications - Teresa R. Zembower
Northwestern University , Chicago, Illinois
2 shared publications A. Chhabra
UT Southwestern Medical Centre, 5323 Harry Hines Blvd, TX, Dallas, USA
1 shared publication- A. Karim Ahmed
Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
1 shared publication A.K. Taneja
Department of Radiology, UT Southwestern Medical Center, Dallas, TX, USA; Baptist Health South Florida and Florida International University, Miami, FL, USA; Radiology Partners and Radiology Associates of South Florida, Miami, FL, USA
1 shared publication- Alexander Perdomo-Pantoja
Department of Neurosurgery, Washington University School of Medicine, 660 S Euclid Ave, Campus Box 8057, St. Louis, MO 63110, USA
1 shared publication
Latest Publications
- 28 April 2026
- Published by Elsevier in Clinical Radiology
- Vol. 99, 107371
Internet image search for musculoskeletal neoplasms: do results return the correct MR sequences?
- 28 April 2026
- Published by Elsevier in Clinical Radiology
- Vol. 99, 107371
Internet image search for musculoskeletal neoplasms: do results return the correct MR sequences?
- 16 December 2025
- Published by Elsevier in Clinical Radiology
- Vol. 94, 107216
Soft-Tissue Tumor Reporting and Data System (ST-RADS): Prospective implementation and diagnostic accuracy
- 16 December 2025
- Published by Elsevier in Clinical Radiology
- Vol. 94, 107216
Soft-Tissue Tumor Reporting and Data System (ST-RADS): Prospective implementation and diagnostic accuracy
- Open Access
- 8 July 2021
- Published by Microbiology Society in Access Microbiology
- Vol. 3 (7) , 000239
The value of repeat patient testing for SARS-CoV-2: real-world experience during the first wave
Introduction. Reports of false-negative quantitative reverse transcription PCR (RT-qPCR) results from patients with high clinical suspension for coronavirus disease 2019 (COVID-19), suggested that a negative result produced by a nucleic acid amplification assays (NAAs) did not always exclude the possibility of COVID-19 infection. Repeat testing has been used by clinicians as a strategy in an to attempt to improve laboratory diagnosis of COVID-19 and overcome false-negative results in particular. Aim. To investigate whether repeat testing is helpful for overcoming false-negative results. Methods. We retrospectively reviewed our experience with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing, focusing on the yield of repeat patient testing for improving SARS-CoV-2 detection by NAA. Results. We found that the yield from using repeat testing to identify false-negative patients was low. When the first test produced a negative result, only 6 % of patients tested positive by the second test. The yield decreased to 1.7 and then 0 % after the third and fourth tests, respectively. When comparing the results produced by three assays, the Centers for Disease Control and Prevention (CDC) SARS CoV-2 RT-qPCR panel, Xpert Xpress CoV-2 and ID NOW COVID-19, the ID NOW assay was associated with the highest number of patients who tested negative initially but positive on repeat testing. The CDC SARS CoV-2 RT-qPCR panel produced the highest number of indeterminate results. Repeat testing resolved more than 90 % of indeterminate/invalid results. Conclusions. The yield from using repeat testing to identify false-negative patients was low. Repeat testing was best used for resolving indeterminate/invalid results.
- 8 July 2021
- Published by Microbiology Society in Access Microbiology
- Vol. 3 (7) , 000239
Open AccessThe value of repeat patient testing for SARS-CoV-2: real-world experience during the first wave
Introduction. Reports of false-negative quantitative reverse transcription PCR (RT-qPCR) results from patients with high clinical suspension for coronavirus disease 2019 (COVID-19), suggested that a negative result produced by a nucleic acid amplification assays (NAAs) did not always exclude the possibility of COVID-19 infection. Repeat testing has been used by clinicians as a strategy in an to attempt to improve laboratory diagnosis of COVID-19 and overcome false-negative results in particular. Aim. To investigate whether repeat testing is helpful for overcoming false-negative results. Methods. We retrospectively reviewed our experience with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing, focusing on the yield of repeat patient testing for improving SARS-CoV-2 detection by NAA. Results. We found that the yield from using repeat testing to identify false-negative patients was low. When the first test produced a negative result, only 6 % of patients tested positive by the second test. The yield decreased to 1.7 and then 0 % after the third and fourth tests, respectively. When comparing the results produced by three assays, the Centers for Disease Control and Prevention (CDC) SARS CoV-2 RT-qPCR panel, Xpert Xpress CoV-2 and ID NOW COVID-19, the ID NOW assay was associated with the highest number of patients who tested negative initially but positive on repeat testing. The CDC SARS CoV-2 RT-qPCR panel produced the highest number of indeterminate results. Repeat testing resolved more than 90 % of indeterminate/invalid results. Conclusions. The yield from using repeat testing to identify false-negative patients was low. Repeat testing was best used for resolving indeterminate/invalid results.
- Open Access
- 15 January 2021
- Published by Springer Nature in Research Square
Molecular Detection, not Extended Culture Incubation, Contributes to Diagnosis of Fungal Infection
Background. Despite its low sensitivity, fungal culture remains one of the key methods for diagnosis and treatment of fungal infections, as it identifies the etiology at the genus and species level and offers susceptibility testing. The Manual of Clinical Microbiology recommends that fungal culture screening for all pathogens should routinely be held for 4 weeks to maximize the recovery of slow-growing species. Information on the optimal fungal culture time in this era of expansion of immunocompromised populations is lacking. We reviewed our experience with fungal culture to determine the optimal culture incubation time. In addition, our experience of broad-range ITS PCR for diagnosis of culture-negative fungal infections was also reviewed.Method. Fungal culture and ITS PCR results from January 1, 2013, to December 31, 2017, were reviewed.Results. Ninety-six percent of positive cultures (4058) were detected in the first 7 days of incubation. During the second week of incubation, 2.8% of positives (111) were detected from day 8 to day 10, and 1.7% (71) were detected from day 11 to day 14. Only 0.1% of positive culture were detected in the third week of incubation, and no positive culture was detected in the fourth week of incubation. No clinically significant fungal isolates were recovered after 14 days. Clinically significant pathogens were detected in 0.2% of culture-negative samples by ITS PCR.Conclusion. Extending culture incubation beyond 2 weeks did not generate clinically relevant results. When culture failed to make a laboratory diagnosis, broad-range internal transcribed spacer (ITS) rRNA gene PCR followed by sequencing produced clinically significant results.
- 15 January 2021
- Published by Springer Nature in Research Square
Open AccessMolecular Detection, not Extended Culture Incubation, Contributes to Diagnosis of Fungal Infection
Background. Despite its low sensitivity, fungal culture remains one of the key methods for diagnosis and treatment of fungal infections, as it identifies the etiology at the genus and species level and offers susceptibility testing. The Manual of Clinical Microbiology recommends that fungal culture screening for all pathogens should routinely be held for 4 weeks to maximize the recovery of slow-growing species. Information on the optimal fungal culture time in this era of expansion of immunocompromised populations is lacking. We reviewed our experience with fungal culture to determine the optimal culture incubation time. In addition, our experience of broad-range ITS PCR for diagnosis of culture-negative fungal infections was also reviewed.Method. Fungal culture and ITS PCR results from January 1, 2013, to December 31, 2017, were reviewed.Results. Ninety-six percent of positive cultures (4058) were detected in the first 7 days of incubation. During the second week of incubation, 2.8% of positives (111) were detected from day 8 to day 10, and 1.7% (71) were detected from day 11 to day 14. Only 0.1% of positive culture were detected in the third week of incubation, and no positive culture was detected in the fourth week of incubation. No clinically significant fungal isolates were recovered after 14 days. Clinically significant pathogens were detected in 0.2% of culture-negative samples by ITS PCR.Conclusion. Extending culture incubation beyond 2 weeks did not generate clinically relevant results. When culture failed to make a laboratory diagnosis, broad-range internal transcribed spacer (ITS) rRNA gene PCR followed by sequencing produced clinically significant results.
- 1 January 2021
- Published by Elsevier in World Neurosurgery
- Vol. 145, e21-e31
First Report of Pharmacogenomic Profiling in an Outpatient Spine Setting: Preliminary Results from a Pilot Study
- 1 January 2021
- Published by Elsevier in World Neurosurgery
- Vol. 145, e21-e31
First Report of Pharmacogenomic Profiling in an Outpatient Spine Setting: Preliminary Results from a Pilot Study
- Open Access
Seroprevalence and Correlates of SARS-CoV-2 Antibodies in Healthcare Workers in Chicago
Background: Identifying factors associated with SARS-CoV-2 infection among healthcare workers (HCW)s may help health systems optimize SARS-CoV-2 infection control strategies. Methods: We conducted a cross-sectional analysis of baseline data from the Northwestern HCW SARS-CoV-2 Serology Cohort Study. The Abbott Architect Nucleocapsid IgG assay was used to determine seropositivity. Logistic regression models (unadjusted and adjusted for demographics and self-reported community exposure to COVID-19) were fit to quantify the associations between occupation group, healthcare delivery tasks, and community exposure and seropositive status. Results: 6,510 HCWs, including 1,794 nurses, and 904 non-patient facing administrators participated. The majority were women (79.6%), 74.9% were white, 9.7% were Asian, 7.3% were Hispanic and 3.1% were Black. The crude prevalence rate of seropositivity was 4.8% (95% confidence interval (CI): 4.6%-5.2%). Out-of-hospital exposure to COVID-19 occurred in 9.3% of HCWs and was strongly associated with seropositivity (OR=4.7, 95% CI: 3.5-6.4). When compared to administrators, nursing was the only occupation group with a significantly higher adjusted-odds (OR: 1.9, 95% CI: 1.3-2.9) of seropositivity. Exposure to COVID-19 patients was reported by 37.8% of participants and was associated with higher positivity than those not exposed (OR= 2.2, 95% CI: 1.6-3.0). Being exposed to patients receiving high-flow oxygen therapy, and hemodialysis also remained significantly associated with a 45% and 57% higher odds for seropositive status, respectively. Conclusions: Exposure to COVID-19 patients, and longer duration patient therapies were each associated with higher risk for seropositive status; however, the community burden of COVID-19 remains a significant source of exposure to SARS CoV-2 infection among HCWs in Chicago.
Open AccessSeroprevalence and Correlates of SARS-CoV-2 Antibodies in Healthcare Workers in Chicago
Background: Identifying factors associated with SARS-CoV-2 infection among healthcare workers (HCW)s may help health systems optimize SARS-CoV-2 infection control strategies. Methods: We conducted a cross-sectional analysis of baseline data from the Northwestern HCW SARS-CoV-2 Serology Cohort Study. The Abbott Architect Nucleocapsid IgG assay was used to determine seropositivity. Logistic regression models (unadjusted and adjusted for demographics and self-reported community exposure to COVID-19) were fit to quantify the associations between occupation group, healthcare delivery tasks, and community exposure and seropositive status. Results: 6,510 HCWs, including 1,794 nurses, and 904 non-patient facing administrators participated. The majority were women (79.6%), 74.9% were white, 9.7% were Asian, 7.3% were Hispanic and 3.1% were Black. The crude prevalence rate of seropositivity was 4.8% (95% confidence interval (CI): 4.6%-5.2%). Out-of-hospital exposure to COVID-19 occurred in 9.3% of HCWs and was strongly associated with seropositivity (OR=4.7, 95% CI: 3.5-6.4). When compared to administrators, nursing was the only occupation group with a significantly higher adjusted-odds (OR: 1.9, 95% CI: 1.3-2.9) of seropositivity. Exposure to COVID-19 patients was reported by 37.8% of participants and was associated with higher positivity than those not exposed (OR= 2.2, 95% CI: 1.6-3.0). Being exposed to patients receiving high-flow oxygen therapy, and hemodialysis also remained significantly associated with a 45% and 57% higher odds for seropositive status, respectively. Conclusions: Exposure to COVID-19 patients, and longer duration patient therapies were each associated with higher risk for seropositive status; however, the community burden of COVID-19 remains a significant source of exposure to SARS CoV-2 infection among HCWs in Chicago.
- Open Access
- 1 June 2020
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 69 (6) , 824-829
Optimizing a real-time PCR assay for rapid detection of Candida auris in nasal and axillary/groin samples
Introduction. Candida auris is an emerging fungal pathogen. The organism can cause invasive infections associated with high mortality, has been implicated in outbreaks in healthcare settings and is frequently resistant to multiple antifungal agents, making it a significant challenge to infection prevention and patient treatment. Aim. To implement a real-time PCR assay for detection of C. auris in patient surveillance samples collected with the Copan Liquid Amies elution swab (ESwab) collection and transport system. Methodology. We optimized a real-time PCR testing procedure based on the sample collection device used in our institution. Results . ESwab transport medium was strongly inhibitory to the real-time PCR. Removing the medium with centrifugation, followed by suspending the pellet in PBS-BSA buffer (concentration 1 %), sufficiently eliminated the inhibition. The manual sample preparation method, freeze–thaw followed by mechanical disruption, allowed the detection of C. auris at the lowest cell concentration. Conclusion . The optimized procedure was used to test 1414 patient surveillance samples. The real-time PCR detected all culture-positive samples with 100 % sensitivity and 100 % specificity.
- 1 June 2020
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 69 (6) , 824-829
Open AccessOptimizing a real-time PCR assay for rapid detection of Candida auris in nasal and axillary/groin samples
Introduction. Candida auris is an emerging fungal pathogen. The organism can cause invasive infections associated with high mortality, has been implicated in outbreaks in healthcare settings and is frequently resistant to multiple antifungal agents, making it a significant challenge to infection prevention and patient treatment. Aim. To implement a real-time PCR assay for detection of C. auris in patient surveillance samples collected with the Copan Liquid Amies elution swab (ESwab) collection and transport system. Methodology. We optimized a real-time PCR testing procedure based on the sample collection device used in our institution. Results . ESwab transport medium was strongly inhibitory to the real-time PCR. Removing the medium with centrifugation, followed by suspending the pellet in PBS-BSA buffer (concentration 1 %), sufficiently eliminated the inhibition. The manual sample preparation method, freeze–thaw followed by mechanical disruption, allowed the detection of C. auris at the lowest cell concentration. Conclusion . The optimized procedure was used to test 1414 patient surveillance samples. The real-time PCR detected all culture-positive samples with 100 % sensitivity and 100 % specificity.